These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 4468022)

  • 1. Intermittent rifampicin treatment.
    Riska NV; Mattson K
    Bull Int Union Tuberc; 1974 Aug; 49 suppl 1():276-9. PubMed ID: 4468022
    [No Abstract]   [Full Text] [Related]  

  • 2. [Rifampicin--a new antitubercular drug].
    Rózewska M
    Gruzlica; 1970 Feb; 38(2):171-7. PubMed ID: 5436933
    [No Abstract]   [Full Text] [Related]  

  • 3. Editorial: Rifampicin.
    Med J Aust; 1973 Nov; 2(19):876. PubMed ID: 4765871
    [No Abstract]   [Full Text] [Related]  

  • 4. [Comparative histopathological studies of the results of continuous and intermittent treatment with rifampicin in experimental tuberculosis].
    Diaconiţă G; Luţescu L
    Ftiziologia; 1974 May; 23(3):269-80. PubMed ID: 4601851
    [No Abstract]   [Full Text] [Related]  

  • 5. Short-course rifampin and pyrazinamide compared with isoniazid for latent tuberculosis infection: a cost-effectiveness analysis based on a multicenter clinical trial.
    Jasmer RM; Snyder DC; Saukkonen JJ; Hopewell PC; Bernardo J; King MD; Kawamura LM; Daley CL;
    Clin Infect Dis; 2004 Feb; 38(3):363-9. PubMed ID: 14727206
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chemotherapy of tuberculosis for the 1980's.
    Dutt AK; Stead WW
    Prim Care; 1980 Sep; 7(3):513-27. PubMed ID: 7003628
    [No Abstract]   [Full Text] [Related]  

  • 7. [Experimental evidence for Mycobacterium tuberculosis persistence in M. tuberculosis-infected H37RV mice in the treatment with 3 first-line drugs (rifampicin, isoniazid, pyrazinamide)].
    Smirnova TG; Chernousova LN; Andreevskaia SN; Nikolaeva GM
    Probl Tuberk Bolezn Legk; 2004; (3):32-7. PubMed ID: 15338898
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [A new antitubercular agent: rifampicin].
    Favez G
    Schweiz Rundsch Med Prax; 1970 Feb; 59(8):296-7. PubMed ID: 4996719
    [No Abstract]   [Full Text] [Related]  

  • 9. Management of latent tuberculosis infection in immigrants.
    Sterling T; Munsiff SS; Frieden TR
    N Engl J Med; 2003 Mar; 348(13):1289-92; author reply 1289-92. PubMed ID: 12661573
    [No Abstract]   [Full Text] [Related]  

  • 10. Review of the Indian market of anti-tuberculosis drugs: focus on the utilisation of rifampicin-based products.
    Catalani E
    Int J Tuberc Lung Dis; 1999 Nov; 3(11 Suppl 3):S289-91; discussion S317-21. PubMed ID: 10593707
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Results with rifampicin therapy of chronic tuberculosis].
    Böszörményi M
    Orv Hetil; 1973 Sep; 114(37):2215-21. PubMed ID: 4741358
    [No Abstract]   [Full Text] [Related]  

  • 12. Rifapentine--a long-acting rifamycin for tuberculosis.
    Med Lett Drugs Ther; 1999 Feb; 41(1047):21-2. PubMed ID: 10076594
    [No Abstract]   [Full Text] [Related]  

  • 13. Lamivudine enabled isoniazid and rifampicin treatment in pulmonary tuberculosis and hepatitis B co-infection.
    Yu WC; Lai ST; Chiu MC; Chau TN; Ng TK; Tam CM
    Int J Tuberc Lung Dis; 2006 Jul; 10(7):824-5. PubMed ID: 16850548
    [No Abstract]   [Full Text] [Related]  

  • 14. Tuberculosis: guidelines changed for latent TB treatment.
    AIDS Treat News; 2001 Sep; (371):3. PubMed ID: 11668976
    [No Abstract]   [Full Text] [Related]  

  • 15. Rifampin and other drugs for treatment of tuberculosis.
    Med Lett Drugs Ther; 1971 Sep; 13(18):73-4. PubMed ID: 5122869
    [No Abstract]   [Full Text] [Related]  

  • 16. Clinical relevance of reduced bioavailability of rifampicin.
    Bhatt AD; Vaz JA; Padgaonkar KA
    J Assoc Physicians India; 1998 Aug; 46(8):729-31. PubMed ID: 11229285
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Late results of treatment of chronic pulmonary tuberculosis with rifampicin].
    Lachowicz E; Polaczek E; Araszkiewicz W; Kozakow H; Pszonicka A; Styszewska H; Janowiec M; Grabowska R
    Gruzlica; 1973 Jul; 41(7):781-7. PubMed ID: 4730979
    [No Abstract]   [Full Text] [Related]  

  • 18. Status of drug resistance in tuberculosis after the introduction of rifampicin in India.
    Paramasivan CN
    J Indian Med Assoc; 2003 Mar; 101(3):154-6. PubMed ID: 14603961
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Long-term results of treatment for drug-resistant pulmonary tuberculosis in socially adapted patients].
    Khodashova ML; Iuditskiĭ MV; Semenova OV
    Probl Tuberk Bolezn Legk; 2004; (3):26-8. PubMed ID: 15338896
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Anti-tuberculosis 4FDC tablets--mystery to chemistry.
    Dekker TG; Lötter AP
    Int J Tuberc Lung Dis; 2003 Mar; 7(3):205-6. PubMed ID: 12661831
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.